Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 4
2004 1
2005 3
2006 1
2007 2
2008 1
2009 2
2010 1
2011 1
2012 3
2013 3
2015 2
2016 5
2017 3
2018 9
2019 10
2020 5
2021 17
2022 12
2023 13
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean yan yan lu[Author] (75 results)?
Emerging therapeutic agents for advanced non-small cell lung cancer.
Chen R, Manochakian R, James L, Azzouqa AG, Shi H, Zhang Y, Zhao Y, Zhou K, Lou Y. Chen R, et al. Among authors: lou y. J Hematol Oncol. 2020 May 24;13(1):58. doi: 10.1186/s13045-020-00881-7. J Hematol Oncol. 2020. PMID: 32448366 Free PMC article. Review.
Next generation of immune checkpoint inhibitors and beyond.
Marin-Acevedo JA, Kimbrough EO, Lou Y. Marin-Acevedo JA, et al. Among authors: lou y. J Hematol Oncol. 2021 Mar 19;14(1):45. doi: 10.1186/s13045-021-01056-8. J Hematol Oncol. 2021. PMID: 33741032 Free PMC article. Review.
Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study.
Saad MB, Hong L, Aminu M, Vokes NI, Chen P, Salehjahromi M, Qin K, Sujit SJ, Lu X, Young E, Al-Tashi Q, Qureshi R, Wu CC, Carter BW, Lin SH, Lee PP, Gandhi S, Chang JY, Li R, Gensheimer MF, Wakelee HA, Neal JW, Lee HS, Cheng C, Velcheti V, Lou Y, Petranovic M, Rinsurongkawong W, Le X, Rinsurongkawong V, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Antonoff MB, Sepesi B, Lewis J, Wistuba II, Hazle JD, Chung C, Jaffray D, Gibbons DL, Vaporciyan A, Lee JJ, Heymach JV, Zhang J, Wu J. Saad MB, et al. Among authors: lou y. Lancet Digit Health. 2023 Jul;5(7):e404-e420. doi: 10.1016/S2589-7500(23)00082-1. Epub 2023 May 31. Lancet Digit Health. 2023. PMID: 37268451 Free PMC article.
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial.
Aggarwal C, Prawira A, Antonia S, Rahma O, Tolcher A, Cohen RB, Lou Y, Hauke R, Vogelzang N, P Zandberg D, Kalebasty AR, Atkinson V, Adjei AA, Seetharam M, Birnbaum A, Weickhardt A, Ganju V, Joshua AM, Cavallo R, Peng L, Zhang X, Kaul S, Baughman J, Bonvini E, Moore PA, Goldberg SM, Arnaldez FI, Ferris RL, Lakhani NJ. Aggarwal C, et al. Among authors: lou y. J Immunother Cancer. 2022 Apr;10(4):e004424. doi: 10.1136/jitc-2021-004424. J Immunother Cancer. 2022. PMID: 35414591 Free PMC article. Clinical Trial.
Immunotherapies targeting stimulatory pathways and beyond.
Marin-Acevedo JA, Kimbrough EO, Manochakian R, Zhao Y, Lou Y. Marin-Acevedo JA, et al. Among authors: lou y. J Hematol Oncol. 2021 May 12;14(1):78. doi: 10.1186/s13045-021-01085-3. J Hematol Oncol. 2021. PMID: 33980266 Free PMC article. Review.
Editorial: Immunotherapy for NSCLC with oncogenic driver variants.
Du Y, Chu Q, Lou Y, He Y, Hu H, Hu Q, Huang M. Du Y, et al. Among authors: lou y. Front Oncol. 2022 Dec 8;12:1095947. doi: 10.3389/fonc.2022.1095947. eCollection 2022. Front Oncol. 2022. PMID: 36568249 Free PMC article. No abstract available.
Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer.
Li S, de Camargo Correia GS, Wang J, Manochakian R, Zhao Y, Lou Y. Li S, et al. Among authors: lou y. Cancers (Basel). 2023 May 24;15(11):2899. doi: 10.3390/cancers15112899. Cancers (Basel). 2023. PMID: 37296863 Free PMC article. Review.
Protein kinase Cι mediates immunosuppression in lung adenocarcinoma.
Yin N, Liu Y, Weems C, Shreeder B, Lou Y, Knutson KL, Murray NR, Fields AP. Yin N, et al. Among authors: lou y. Sci Transl Med. 2022 Nov 16;14(671):eabq5931. doi: 10.1126/scitranslmed.abq5931. Epub 2022 Nov 16. Sci Transl Med. 2022. PMID: 36383684
97 results